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Immunohistochemistry (IHC) is routinely used to approximate breast cancer intrinsic subtypes, which 
were initially discovered by microarray analysis. However, IHC assessment of oestrogen receptor (ER), 
progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2) status, is a poor surrogate 
of molecular subtype. Therefore, MammaPrint/BluePrint (MP/BP) microarray gene expression profiling is 
increasingly used to stratify breast cancer patients into different treatment groups. In this study, ER/PR status, 
as reported by standard IHC and single-gene mRNA analysis using TargetPrint, was compared with molecular 
subtyping to evaluate the combined use of MP/BP in South African breast cancer patients. Pathological 
information of 74 ER/PR positive, HER2 negative tumours from 73 patients who underwent microarray 
testing, were extracted from a central breast cancer genomics database. The IHC level was standardised by 
multiplying the intensity score (0–3) by the reported proportion of positively stained nuclei, giving a score of 
0–300. Comparison between mRNA levels and IHC determination of ER/PR status demonstrated a significant 
correlation (p<0.001) for both receptors (ER: 0.34 and PR: 0.54). Concordance was shown in 61 (82%) 
cases and discordance in 13 (18%) of the 74 tumours tested. Further stratification by MP/BP identified 49 
(66.2%) Luminal A, 21 (28.4%) Luminal B and 4 (5.4%) Basal-like tumours. Neither IHC nor TargetPrint 
could substitute BP subtyping, which measures the functional integrity of ER and can identify patients with 
false-positive tumours who are resistant to hormone therapy. These findings support the implementation of 
a pathology-supported genetic testing approach combining IHC and microarray gene profiling for definitive 
prognostic and predictive treatment decision-making in patients with early stage breast cancer.
Significance:
• Single-gene genomic oestrogen and progesterone receptor reporting adds limited additional
information to the molecular stratification of breast cancer tumours and does not supersede the
immunohistochemistry results.
• Neither single-gene genomic mRNA nor immunohistochemistry reporting of oestrogen and progesterone 
receptor status can replace the combined use of MammaPrint/BluePrint genomic molecular subtyping.
• Reliable distinction between Luminal A and B type tumours is not possible using immunohistochemistry 
or single-gene genomic mRNA assessment of oestrogen/progesterone and HER2 receptor status.
• Combining immunohistochemistry and microarray gene profiling enables the identification of endocrine 
treatment resistant hormone-positive tumours lacking ERα function (Basal-like), despite positive
expression at the protein and single-gene RNA level.
Introduction
Breast cancer defines a broad spectrum of histological lesions that are considered highly heterogeneous in 
presentation, morphological characteristics, prognosis and therapeutic outcome.1 Microarray-based gene 
expression profiling led to the discovery of intrinsic molecular subtypes underlying the variability in biological 
behaviour and response to treatment amongst breast cancer patients.2,3 
Five distinct subtypes were described by Perou et al.2, although the normal-like subtype was subsequently 
considered to represent normal breast tissue within tumour. Luminal tumours expressed oestrogen receptor (ER) 
and responded to endocrine therapy. While Luminal A tumours show little benefit from the addition of chemotherapy, 
Luminal B tumours display some genetic similarities to Basal-like tumours in that they have a higher risk of being 
hormone resistant and show additional benefit from chemotherapy as demonstrated by the significant pathological 
complete response rate after neo-adjuvant chemotherapy. Human epidermal growth factor receptor-2 (HER2)-
enriched and Basal-like subtypes are considered more aggressive with an unfavourable prognosis, although 
paradoxically exhibiting greater chemosensitivity compared to the Luminal subtype. Basal-like breast cancers are 
inherently resistant to endocrine therapy, and tumours subtyped as HER2 enriched respond to anti-HER2 therapy 
in addition to chemotherapy. Some tumours reported as HER2 positive are subtyped as Luminal B and retain some 
responsiveness to endocrine treatment in addition to chemotherapy and HER2 targeted treatments.4 Borley et al.5 
demonstrated that the HER2 gene copy number provides additional information for stratifying breast cancer patients 
into different treatment groups, because HER2-positive patients with a low degree of HER amplification were shown 
to derive less benefit from trastuzumab (the chemotherapy agent more commonly known as Herceptin®). 
Numerous studies using standard pathology have been performed to identify, with some accuracy, treatable 
molecular subtypes. Suggestions for incorporating markers such as the epidermal growth factor receptor (EGFR), 
proliferation marker Ki67, tumour suppressor gene protein p53, transmembrane tyrosine kinase receptor CD117(c-
kit) and cytokeratin 5/6 into a standard immunohistochemistry (IHC) panel for breast cancer3,6 have not been adopted 
because of poor standardisation. High-quality assessed Ki67 is considered most useful when the indication for 
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adding adjuvant chemotherapy to endocrine treatment is uncertain, but molecular classification can help to identify 
a larger group of early-stage breast cancer patients with low risk of recurrence.7 Some studies suggested that loss 
of progesterone receptor (PR) expression might be indicative of the Luminal B subtype8, but this association has 
not been universally reported. ER, PR and HER2 status have been incorporated into standard pathology reporting 
of breast cancers with reproducible prognostic and predictive value9,10. It is only with the advent of genetic tumour 
profiling that accurate molecular subtyping became part of daily clinical practice. A prospective study performed 
by Whitworth et al.11 proved that the combined use of the 70-gene MammaPrint (MP) and 80-gene BluePrint (BP) 
assays in microarray analysis of mRNA expression may be more accurate than standard IHC to guide treatment 
decisions. Notably, 22% of over 400 breast cancer patients studied were reclassified into a different subgroup 
compared with conventional assessment and showed an improved distribution of response rates in the relevant 
treatment groups. Similar findings were reported by Yao et al.12 Previous studies have shown that mRNA reporting 
of ER, PR and HER2 using microarrays is highly comparable to IHC testing.13-15 However, others have cautioned 
against the preferential use of hormone receptor reports using RNA-based reverse transcription polymerase chain 
reaction (RT-PCR) technology, highlighting discordance with the IHC results and the potential of denying patients 
who were ER or PR positive on IHC the benefit of endocrine therapy.16,17 Application of different methodologies for 
the same purpose therefore requires careful consideration. 
Microarray-based tumour profiling using the 70-gene MP profile has been available in South Africa since 2007 
and, from 2009, local referral criteria were introduced for reimbursement by medical aid providers.18 Initially, 
analysis was performed on fresh tissue only, but since 2012 the use of formalin fixed paraffin embedded (FFPE) 
tissue became available and has become the only method used. A central database was established by using 
an ethics approved protocol for comparative effectiveness studies on data of MP tests requested in southern 
Africa. In addition to ER/PR mRNA reporting by TargetPrint (TP) from 2009, BP – which determines the tumour 
molecular subtype19 – has also become part of the MP service from 2011. BP provides a comprehensive multigene 
expression analysis of the tumour molecular subtypes, which may not be sufficiently reflected by single-gene IHC 
or mRNA testing.20,21 Although our data on HER2 expression indicated a 100% correlation between fluorescence 
in-situ hybridisation (FISH) and microarray testing using TP22, discrepancies in ER/PR reporting between IHC and 
RNA-based RT-PCR techniques23,24 warranted evaluation in this study of the value and potential clinical impact of 
ER and PR status as reported by TP using RNA-based microarray analysis. 
Our aim was to evaluate the combined use of MP/BP in clinical practice using a pathology-supported genetic 
testing approach incorporating ER, PR and HER2 status as part of the above-mentioned referral criteria, called the 
microarray pre-screen algorithm (MPA). ER and PR status as assessed by IHC was compared with that reported by 
TP in order to determine the correlation between the two techniques. We used the BP result to identify the molecular 
subtype and most probable response to therapy and correlated this result to the IHC and TP results. This study is the 
first to correlate IHC and mRNA hormone receptor status in South African breast cancer patients, using microarrays 
performed on FFPE specimens in the context of molecular breast cancer subtyping. As a consequence of the MPA 
employed in southern Africa, which generally excludes patients with ER/PR negative or HER2 positive tumours from 
testing, our series was limited to ER/PR positive, HER2 negative tumours only. South African patients reclassified as 
HER2 positive using TP and reflex FISH in a recent study22 were also excluded from the current analysis. 
Methods
This study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki. 
Ethical approval was granted by the Health and Research Ethics Committee (HREC) of Stellenbosch University 
(reference number N09/06/166).
Study population 
The records of 128 patients with 131 tumours were available in a central breast cancer genomic database, which 
comprised data of all patients referred for MP in southern Africa between 2007 and 2014. The database is maintained 
centrally under a rigorous quality control programme to ensure the integrity of the data. We extracted anonymised 
pathological data of 74 HER2 negative tumours from 73 patients who had TP and BP testing on FFPE tissue. The 
tumour pathology included tumour type, grade and size; ER, PR and HER2 status; MP risk status; TP results for ER, 
PR and HER2; and the molecular subtype as determined by BP.
Immunohistochemistry testing 
Standard pathology reporting of hormone and HER2 receptor status using IHC to measure protein expression levels 
varies amongst different laboratories. To standardise the data for statistical analysis of hormone receptor status, 
estimation of the semi-quantitative expression of ER and PR was performed using the intensity score (0–3), multiplied 
by the reported proportion of positively stained nuclei, thereby calculating a final ER and PR score (0–300). 
Microarray-based gene expression profiling 
Microarray-based gene expression profiling (MP, TP and BP) was performed on 74 FFPE tissue samples obtained from 
73 breast cancer patients, using a pathology-supported genetic testing strategy.18 An experienced pathologist evaluated 
tumour suitability for genomic analysis based on confirmation of a minimum tumour cell content of 30% in accordance 
with compliancy criteria laid out by the US Food and Drug Administration. These samples were transported under an 
export permit to the Netherlands where tumour assessment was performed at the centralised Agendia Laboratory in 
accordance with standard testing protocols.25 mRNA expression for ER and PR is reported on a continuous exponential 
scale from -1 to 1 and values of less than 0 are considered to be negative. 
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Quantitative analysis was performed by comparing the level of mRNA 
for ER and PR as reported by TP with the IHC score. ER and PR 
were considered to be positive when the IHC score was >10 or the 
mRNA score was >0. Qualitative analysis was performed to allow in-
depth evaluation of the relationship between IHC and mRNA compared 
to tumour subtyping, with the aim of determining the clinical implications 
of individual versus combined assessment of pathology and microarray-
based genetic testing. 
Statistical analysis 
Statistical analysis was performed using the Statistica v.13 software 
package. Observer agreement measures for IHC testing to determine 
hormone receptor status and microarray-based mRNA readout 
assessment were calculated from two-way contingency table analysis.26 
The relationship between protein expression (IHC) and mRNA (TP) 
levels was assessed using Spearman rank correlation analysis. 
A possible association between loss of PR expression in ER-positive 
cases (ER+/PR-) and the high-risk Luminal B subtype as determined by 
microarray analysis was further assessed. Results corresponding to a 
p<0.05 were considered statistically significant. 
Results
Description of tumour pathology in relation to molecular 
subtype 
All tumours were ER and/or PR positive on IHC. Analysis of the 
pathological characteristics of the 74 HER2 negative tumours subjected 
to TP (ER, PR and HER2 status) and BP using FFPE specimens is 
presented in Table 1. Molecular subtyping using the BP microarray test 
stratified 49 (66.2%) tumours as Luminal A, 21 (28.4%) as Luminal B 
and 4 (5.4%) as Basal-like. In the patient with multi-focal pathology, one 
tumour was designated Luminal A and the other Luminal B.
Table 1:  Comparison of tumour morphology and grade between 
breast cancer subtypes according to the BluePrint microarray 
in 74 tumour specimens from 73 South African breast 
cancer patients 
Total Luminal A Luminal B Basal-like
n (%) n (%) n (%) n (%)
Total (n) 74 (100) 49 (66.2) 21 (28.4) 4 (5.4)
Tumour morphology
Ductal 62 (83.8) 41 (67.2) 17 (27.9) 4 (6.5)
Lobular, pleomorphic 3 (4.1) 1 (33.3) 2 (66.7) 0 (0.0)
Lobular, classic 9 (12.2) 7 (77.8) 2 (22.2) 0 (0.0)
Tumour grade
1 17 (23) 14 (82.4) 3 (17.6) 0 (0.0)
2 35 (47.2) 24 (68.6) 10 (28.6) 1 (2.8)
3 15 (20.3) 6 (40.0) 6 (40.0) 3 (20)
n/a 7 (9.5) 5 (71.4) 2 (28.6) 0 (0.0)
Comparative analysis of ER and PR status
A quantitative comparison between mRNA levels and IHC determination 
of ER and PR is shown in Figures 1 and 2. Spearman R-values were 0.34 
for ER and 0.54 for PR (p<0.001), indicating the correlation between 
mRNA and IHC. Table 2 indicates the mean values for IHC and mRNA 
scores for both ER and PR according to tumour subtype. Significant 
differences were observed amongst tumour subtypes for all variables 
except for mRNA expression of PR. Fisher’s Least Significant Difference 
Test confirmed significant differences between Basal type and Luminal 
types with no difference seen between Luminal A and B subtypes. The 
sum of ER and PR scores, which resulted in maximum values of 600 
and -2 to +2 for IHC and mRNA, respectively, indicated significant 
differences between Basal and Luminal tumours. Comparably, no 
differences were shown between Luminal A and B molecular subtypes. 
The combined score also amplified the differences between the groups, 
as illustrated in Figure 3.
Figure 1:  Scatterplot showing the relationship between oestrogen receptor 
(ER) immunohistochemistry (IHC) score and mRNA score; 
Spearman R=0.34 (p=0.00).
Figure 2:  Scatterplot showing the relationship between progesterone 
receptor (PR) immunohistochemistry (IHC) score and mRNA 
score; Spearman R=0.54 (p=0.00).
Figure 3:  Combined oestrogen (ER) and progesterone receptor (PR) 
scores for immunohistochemistry (IHC) (0–600) and TargetPrint 
(-2 to +2), in relation to tumour molecular subtype determined 
using BluePrint.
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Table 2:  Mean values of oestrogen receptor (ER), progesterone receptor 
(PR) and combined scores for immunohistochemistry (IHC) 








ER IHC score 0–300 249.3878 232.1429 117.5*
PR IHC score 0–300 222.4898 181.1905 73.5*
ER RNA score -1 to 1 0.381 0.399 -0.165*
PR RNA score -2 to 2 0.391 0.332 0.058
Combined ER and PR IHC 
score 0–600
471.877 413.333 191.0*
Combined ER and PR RNA 
score -2 to 2
0.772857 0.773 -0.1075*
*p<0.01. In all these cases, Basal type was found to differ significantly from both 
Luminal A and B subtypes. 
A qualitative analysis was performed to evaluate the relationship 
between IHC and mRNA in relation to tumour subtyping. Table 3 provides 
a summary of the data. Of the 74 tumours, ER and PR status was 
concordant in 61 (82%) and discordant in 13 (18%). In the concordant 
group, 39 (64%) were Luminal A, 17 (31%) were Luminal B and 3 (5%) 
were Basal breast cancer subtypes. In the discordant group (n=13), 
three tumours were ER and PR negative on mRNA, with one being 
Luminal A, one being Luminal B and the other being a Basal-subtype. Of 
these 13 discordant tumours, 10 (77%) were Luminal A, 2 (15%) were 
Luminal B and 1 (8%) was a Basal-type.
Table 3:  Tumour classification according to molecular subtyping 
(BluePrint) assessed in relation to ER/PR status in IHC/TargetPrint 
















ER+/PR+ 56 (91.8) 39 (69.6) 17 (30.4)
ER+/PR- 3 (4.9 ) 0 2 (67.7) 1 (33.3)
ER-/PR+ 2 (3.2 ) 0 0 2 (100)
Discordance 13 (17.6)




ER+/PR- 5 (6.8) (3)ER+/PR+ 3 (60)
(2)ER-/PR- 1 (20) 1 (20)
ER-/PR+ 1 (1.4) (1)ER+/PR+ 1(100)
ER/PR, oestrogen/progesterone receptor; IHC, immunohistochemistry
The relationship between IHC and mRNA status versus tumour subtype 
is indicated in Figure 4. Importantly, none of the ER+/PR+ tumours 
determined on IHC were reported as Basal subtype breast cancers. 
When either ER or PR expression was lost, on both IHC and mRNA, 
there was a 57% (4 out of 7) risk of a Basal subtype. No predictive 
pattern in hormone receptor expression determined by IHC could be 
identified to distinguish Luminal A from Luminal B tumours identified 
through combined use of MP/BP.
Figure 4:  Flow diagram showing the relationship of 
immunohistochemistry (IHC) and TargetPrint results 
on molecular subtype determined by combined use of 
MammaPrint and the BluePrint functional subtype classifier.
Discussion
Ongoing validation of emerging genomic technologies against current 
standards in breast cancer pathology is an important research focus. In 
South Africa, an increased level of confidence based on growing clinical 
experience supported the incorporation of MP/BP19,27 into routine clinical 
practice. Integration of these results into treatment decision may lead 
to a change in therapy in one of every two early-stage breast cancer 
patients treated in South Africa.28 In the present study, the molecular 
subtype based on BP was used as an indicator of the expected response 
to therapy. The Luminal type of breast cancer is expected to respond to 
endocrine therapy, whereas the Basal subtype is inherently resistant to 
endocrine therapy. IHC and TP results were evaluated for their ability to 
predict a non-Luminal subtype. 
In contrast to previous results from our research group showing a 100% 
correlation in HER2 status between FISH and TP, irrespective of whether 
fresh or FFPE specimens were used22, our current qualitative results 
show 18% discordance between the IHC and TP determination of ER 
and PR status. More importantly, three (4%) of the ER+/PR+ tumours 
as determined by IHC/FISH were ER-/PR- on TP regardless of being 
a Luminal-type. If the TP results were interpreted without the IHC and/or BP 
results, the results could have a major implication on treatment decision-
making for the patients. It is therefore important to realise that determination 
of mRNA status for ER and PR using single-gene mRNA analysis does 
not necessarily translate to protein expression or reflect the presence of a 
functioning receptor protein.29 Because molecular subtyping performed 
through BP is enriched for several genes involved in ER function, the 
combined score of 80 genes included in the BP microarray profile 
provides a better indication of an intact ER-mediated kinase pathway 
and subsequent response to endocrine therapy.20
Reasons for the apparent discrepancy between mRNA expression and 
receptor protein levels based on IHC can be found in our quantitative 
analyses which indicated that ER and PR protein expression levels varied 
substantially in relation to mRNA levels. In Figure 1, there were eight 
tumours with mRNA scores of <0, indicating ER mRNA negativity, but 
with a mean IHC score of 156 (0–300), and only two had an IHC score 
<10. As mRNA levels increased above 0, there was only one Luminal A 
tumour with an IHC score of 0. For PR there seemed to be better correlation 
of low mRNA levels to the IHC score, with 6 out of 9 tumours reported 
with a mRNA score <0 showing an IHC score of 0. Similar results were 
reported in a study using quantitative immunofluorescence for measuring 
mRNA in situ by Bordeaux et al.30 These authors found a nonlinear 
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relationship between ERα protein expression and mRNA levels on tissue 
sections visualised using RNA scope probes. In a similar finding to this 
study, protein expressions varied considerably at very low levels of RNA. 
In their analysis, mRNA did not show any prognostic value but had some 
predictive value above and beyond that of the ERα protein expression. 
The presence of a splice variant in the ER gene might also influence the 
apparent ER protein expression, as previously described by Groenendijk 
et al.31 Several ER splicing variants have been reported in the literature, 
resulting in one or more exons being omitted from the ER mRNA. 
Advanced techniques such as exome sequencing might be particularly 
effective in identifying these abnormalities.32 Antibodies used to detect 
ER protein during routine IHC assessment rely on epitope recognition 
encoded by the first exon of the ER gene; therefore, antibody binding at 
these sites will produce a positive ER result, despite the lack of normal 
ER functionality as a result of a splice variant. Similarly, RNA methods 
based on single-gene identification of ER status such as TP (microarray, 
previously provided as a separate readout with MP) and Oncotype DX 
(RT-PCR, included in 21-gene assay) will not routinely detect such 
variants. The ability of microarray analysis to detect functional ERα 
activity,	 could	explain	why	a	patient	with	 the	ERΔE7	splice	variant	 as	
noted by Groenendijk et al.31 was classified as high risk by MP, but low 
risk by Oncotype DX (Recurrence Score of 8). Comprehensive genomic 
evaluation using multi-gene tests such as MP/BP is needed to identify 
these hormone-resistant tumours. This justifies recent discontinuation 
of TP and introduction of the European Conformity (CE)-marked next-
generation sequencing based MP/BP® (Agendia, Inc.). 
Numerous technical factors have an influence on the accuracy of 
standard IHC reporting, including the effect of cold ischaemic time on ER 
epitope availability, resulting in false low levels of protein expression.33,34 
Different samples used for initial IHC versus subsequent receptor status 
determination using TP, could contribute to discordant results as some 
authors have reported high false positive and negative rates when testing 
was performed on tissue obtained from core needle biopsies as opposed 
to resected specimens.35 Sample differences might also play a role as 
some of the patients had the initial receptor status reported on core needle 
biopsies whereas TP was performed on the resection specimen. In most 
units, however, this is an accepted practice with good correlation, although 
it should be avoided in ER and PR negative tumours.36
Variations in individual ER and PR levels measured by IHC or mRNA levels 
did not discriminate between Luminal A and B tumours. Basal tumours had 
significantly lower scores for ER and PR on IHC as well as mRNA levels for 
ER. Utilising a summative ER/PR score for both IHC and mRNA allowed 
better discrimination between Basal tumours and Luminal tumours. When 
this combined score was employed, as illustrated in Figure 3, four out 
of	 six	 tumours	with	 an	 IHC	≤	270	and	mRNA	≤0.1	were	Basal	while	
the remaining two were Luminal B breast cancer subtypes. This was 
also reflected in our qualitative analysis. All the tumours which were 
ER+/PR+ using IHC were Luminal A or B subtypes and the additional 
results provided by TP did not add any further information to assist in 
distinguishing Luminal A from Luminal B tumours identified by BP. In cases 
where ER or PR was negative on IHC, TP did add some additional value 
although the numbers in this group were limited (n=11). In this group, all 
four tumours for which TP showed an ER+/PR+ profile, were Luminal A 
and would potentially gain little or no benefit from additional chemotherapy. 
The remainder were either Luminal B or Basal subtypes, suggesting the 
addition of chemotherapy to the treatment plan. 
Interpretation of the results is limited by a relatively small sample size as 
well as pre-selection of hormone-positive and HER2 negative patients 
in compliance with the MPA developed for reimbursement purposes in 
South Africa.18 This precluded evaluation of the effect TP might have 
on reclassification of IHC ER-/PR- tumours22, possibly classifying some 
of these as hormone receptor positive or Luminal type supported by 
BP results. The main strength of the study lies in the reclassification 
of a subset of patients into the Luminal B and Basal-like subtypes who 
require more aggressive treatment compared to patients with Luminal A 
type tumours. Because the 80-gene BP profile is enriched in ER-target 
genes and measures the functional integrity of ER, it has the potential 
to identify a subgroup of breast cancer patients who are ER-positive 
by IHC and/or single-gene mRNA expression analysis but would fail to 
respond to hormone treatment.31 
In conclusion, our results show that in contrast to the added value of TP 
as a second opinion for HER2 status22, single-gene microarray readout of 
ER/PR status provided little additional information beyond that obtained 
from standard IHC results and performed poorly in predicting molecular 
tumour subtype. If genomic hormone receptor status alone would be 
used in clinical decision-making, it is possible that some patients might 
be erroneously denied endocrine therapy. However, in tumours for which 
ER or PR expression was lost on both IHC and TP, the molecular subtype 
determined by BP was less likely to be Luminal A, thus indicating the 
potential benefit of adjuvant chemotherapy. Basal tumours can potentially 
be identified by utilising the sum of the ER and PR results in both IHC 
and	mRNA	and	selecting	tumours	for	which	IHC≤270	and	mRNA≤0.1,	
or the flow diagram in Figure 4 can be employed. Accurate distinction 
between Luminal A and B molecular subtypes, and identification of the 
Basal-type despite apparent positive ER status on IHC and TP noted 
in at least one South African patient, were only possible by using the 
BP 80-gene profile. It was our consistent observation that loss of PR 
expression on IHC was not indicative of the Luminal B subtype. TP 
provided limited additional information compared to IHC, which justifies 
recent discontinuation of single-gene mRNA microarray testing of the 
ER, PR and HER2 genes now incorporated into the 80-gene BP profile.
The clinical relevance of a pathology-supported genetic testing approach 
to breast cancer management, combining microarray-based analysis 
as ancillary to existing clinico-pathological risk stratification and 
prognostication tools, is supported by the results presented in this 
study. The routine implementation of genomic profiling alongside standard 
pathology tests may increase clinician confidence in treatment decision-
making and ultimately optimise individualised management of early-stage 
breast cancer patients by identifying molecular subgroups more accurately. 
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